https://www.statnews.com/2021/01/23/asymptomatic-i

New Post Public Reply Private Reply Replies (0) Message Board
Crunch55
304
https://www.statnews.com/2021/01/23/asymptoma...f-control/

STATTry STAT+



CORONAVIRUS

FIRST OPINION

THE READOUT LOUD

HEALTH

FIRST OPINION
The day we let Covid-19 spin out of control
By DANIEL P. ORAN and ERIC J. TOPOL

JANUARY 23, 2021

Reprints
NY antibody testing
A woman holds her hand out to have blood collected for Covid-19 antibodies at a drive-thru site in Hempstead, N.Y., in April.
SETH WENIG/AP
Jan. 24 marks the one-year anniversary of a momentous but largely unnoticed event in the history of the Covid-19 pandemic: the first published report of an individual infected with the novel coronavirus who never developed symptoms. This early confirmation of asymptomatic infection should have set off alarm bells and profoundly altered our response to the gathering storm. But it did not. One year later we are still paying the price for this catastrophic blunder.

At least one of three people infected with SARS-CoV-2, the virus that causes Covid-19, do not develop symptoms. That’s the conclusion of a review we just published in the Annals of Internal Medicine. It summarizes the results of 61 studies with more than 1.8 million people.

But during much of the pandemic, fierce resistance — and even outright denialism — in acknowledging this not-so-typical disease pattern led to ineffective testing practices that allowed the pandemic to spin out of control.

On Jan. 28, 2020, Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said, “In all the history of respiratory-borne viruses of any type, asymptomatic transmission has never been the driver of outbreaks. … Even if there’s a rare asymptomatic person that might transmit, an epidemic is not driven by asymptomatic carriers.”

Related: The coronavirus at 1: A year into the pandemic, what scientists know about how it spreads, infects, and sickens
This was a widely held view. On June 8, 2020, a senior official of the World Health Organization called asymptomatic transmission “very rare.”

To his credit, Fauci was among those who immediately criticized this remark. Based on epidemiological data that had become available since his earlier comments, he said it was “not correct” to characterize asymptomatic transmission as rare.

In June, when we published a report of 16 cohorts with sizable proportions of asymptomatic infection and suggested that it might play a role in the progression of the pandemic, several researchers wrote letters to the editor demanding that our paper be retracted.

Today, the best evidence suggests that about half of Covid-19 cases are caused by infected people who do not have symptoms when they pass on the virus. These symptom-free spreaders are roughly divided between those who later develop symptoms, known as pre-symptomatic individuals, and those who never develop symptoms.

While the importance of asymptomatic infection in understanding Covid-19 has been surprising to some, infectious disease experts have long known that infection without symptoms is common in many illnesses. More than 90% of people infected with poliovirus have no symptoms. And about 75% of influenza infections have been estimated to be asymptomatic. Yet these important precedents have largely been ignored.

Asymptomatic coronavirus infection is not necessarily benign. Several studies have reported abnormal lung scans in those infected without symptoms, as well as myocarditis, a type of heart inflammation. The long-term health implications of asymptomatic infection aren’t known.

Even though knowledge about asymptomatic infection has greatly evolved, tactics for combating the pandemic have not. It is now obvious that testing only those with symptoms, as was common early in the pandemic, is a mistake because it ignores the invisible legions of infected people who have no symptoms. But it is not enough to merely increase the number of tests. The problem is that current testing practices are ill-suited to detecting and containing asymptomatic infection.

Virtually all of the coronavirus testing performed in the U.S. looks for the genetic material of the virus using the polymerase chain reaction (PCR). It requires expensive equipment and trained technicians. Results are typically returned days — sometimes even weeks — after the test. That means people learn they have been infected with SARS-CoV-2 long after they may have passed the virus to others. Testing becomes more about accounting — tallying the number of detected infections — than about containing the spread of the virus.

Related: What we now know — and don’t know — about the coronavirus variants
What’s needed is a pivot to a different type of testing. Antigen tests, which look for a bit of coronavirus protein, cost just a few dollars each and can yield results in minutes. Like home pregnancy tests, they require minimal instruction. Antigen tests are ideal for spotting people who are infectious, rather than those who may be long past the infectious phase of Covid-19, or who harbor such low levels of the virus that they are unlikely to infect others.

Inexpensive rapid home tests would help infected people isolate themselves before they could spread the virus. Frequent testing — at least several times per week — is essential, as demonstrated by successful testing efforts at some universities, which have enabled students to return to campus. A new focus on self testing, in combination with financial assistance and perhaps even temporary housing for isolation, would directly address the problem of asymptomatic infection.

The rollout of Covid-19 vaccines brings with it the risk of a new wave of asymptomatic infections. The two vaccines authorized by the Food and Drug Administration have been proven to prevent illness, but not asymptomatic infection. Even after vaccination, the coronavirus may still temporarily take up residence in the lining of the respiratory tract, making it possible to infect others. Preliminary results from one vaccine trial seem encouraging, with an apparent two-thirds reduction in asymptomatic infection after the first dose. But many other studies are underway.

There is no time machine that would allow us to return to Jan. 24, 2020, and make the plans we should have made, which would have acknowledged the importance of asymptomatic infection. But it is not too late to recognize the blunder and move aggressively toward testing practices that will help end the pandemic.

Daniel P. Oran is a member of the digital medicine group at Scripps Research Translational Institute, of which Eric J. Topol is founder and director.

About the AuthorsReprints
Daniel P. Oran
@danieloran
Eric J. Topol
etopol@scripps.edu
@EricTopol
Tags
CORONAVIRUS
PUBLIC HEALTH
Leave a Comment
Name
Email Address
Comment

Notify me of followup comments via e-mail
Ron Hovet
JANUARY 24, 2021 AT 1:36 PM
I’m 60 years old, I’ve had 5 heart attacks (4 stent implants) and a pericardial window. I’m also a diabetic type II and have high blood pressure. I’m very nervous when out in public due to the virus. How can I get the vaccine or antibody and which treatment type would be the most effective? I live in Arizona but have no idea how to qualify for the vaccine as a “high risk patient”. Any information would be greatly appreciated, thank you.

Reply
Jake Steeley
JANUARY 24, 2021 AT 11:34 AM
How about this: Forget about the stats, the politics, the reasons and whatever TV channel you watch and 1. Wear a mask, 2. Get your shots ASAP and 3. Be careful + mindful around other people until COVID is gone.

Basic. Common. Sense.

Is this too much to ask?

Reply
Tom Trifik
JANUARY 24, 2021 AT 11:58 AM
Jake, sadly reports have indicated that the rapidly mutating COVID Virus will be ”gone” when the Entire Human Race + All Warm Blooded Animals are no more!

Until that hopefully far future day happens COVID & its Mutations will ALWAYS be around like the Common Cold and the yearly Outbreaks of Various Influenza Viruses!

Meanwhile, invest in Companies involved with Protective Face Masks, Respiratory Therapies, E-Commerce, Online Tele-Health, Sequestered Care Facilities, Vaccines & Gene Therapy, and Home Use Virus Test Kits!

Joel Hirschhorn
JANUARY 24, 2021 AT 10:28 AM
Learn all the horrifying facts about the Pandemic Blunder in the forthcoming book by Joel S Hirschhorn; the chief screw up was not fully supporting early home treatment that could have saved 70 to 80 percent of covid deaths.

Reply
Kay rogers
JANUARY 24, 2021 AT 10:24 AM
OR maybe China’s lying to the world about a virus that started in their country refused to let WHO and the CDC in to help which could possibly have helped contain it or at least spread the word to the rest of the planet that this was no ordinary flu virus. LACK OF INFORMATION KILLS so start with a communist country willing to kill to protect its secrets.

Reply
Tom Trifik
JANUARY 24, 2021 AT 11:35 AM
Re: “…. so start with a Communist country willing to kill to protect its secrets.”

Hey! That’s OKAY

Quantum Materials Corp. (QTMM) Stock Research Links

QTMM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DeFi Technologies Gains More Time for Nasdaq Compliance

Updated Category News Views 1

DeFi Must Step Up To Meet Compliance Challenge Alright, folks, here's the scoop: DeFi Technologies just picked up another 180 days from Nasdaq to get its act together and hit that crucial one-buck minimum bid price. It's like getting extra time on a pop quiz you forgot to study for—useful, but no guarantee they'll pass. What Led to the Extra Time? These guys over at...

Continue Reading
NOVOSENSE's Bold Performance Amid Rapid IC Demand

Updated Category News Views 0

Surge in Revenue Growth Marks a Milestone for NOVOSENSE Give a pat on the back to NOVOSENSE (HKEX: 02676), because reporting a robust 66.73% bump in first-half revenue isn't small potatoes in today's tech landscape. This translates to around $374.54 million rolling into their coffers, which is quite a spectacle if you're watching the trend of sequential revenue growth...

Continue Reading
FirstEnergy's Bold Move: Dormo Joins to Boost Power

Updated Category News Views 3

Changing the Game in Power Generation In the ever-shifting landscape of power generation, having a seasoned player at the helm can be the difference between stagnation and growth. FirstEnergy Corp. (NYSE:FE) has tapped Jon Dormo as its Vice President of Generation Project Development. The mission? Overhaul and expand projects to meet the increasing demands for...

Continue Reading
Smithfield's Foreign Lobbying Interests Unveiled Amid Uproar

Updated Category News Views 2

A Behind-the-Scenes Drama Over Lobbying Disclosure Something's fishy beneath the surface of Smithfield Foods' recent lobbying debacle. The Center for Responsible Food Business (CRFB) has turned the spotlight on some shady practices, and folks, it ain't pretty. Smithfield's lobbyists had been ducking disclosure rules apparently meant to keep track of foreign influence. Who...

Continue Reading
TECNO Unleashes New Laptops & Phones at IFA 2026

Updated Category News Views 1

A Bold Leap by TECNO You walk into the IFA ShowStoppers 2026 event, and what’s greeting you is a flashy splash of next-gen tech from TECNO. Now, if you thought this brand was only about pushing phones, you're in for a ride. TECNO has crashed the laptop party with its new MEGABOOK T15 360 Series, showing it’s more than capable of straddling the tablet and laptop worlds...

Continue Reading
Russo Pushes $100M Boost for Women Entrepreneurs in FL

Updated Category News Views 1

Russo's Big Bet on Women-led Ventures There's nothing quite like a political shake-up promising to dig into government pockets without slamming taxpayers. Frank Russo, tossing his hat for Florida's governorship, is betting big on women entrepreneurs with a bold move—a $100 million Women’s Entrepreneurship Initiative. No new taxes, he claims, just smart financial...

Continue Reading
EzCheckPrinting Boosts Remote Check Solutions Cost-Effectively

Updated Category News Views 2

Navigating the Check Printing Landscape Let's dive right into the changing realities of the workspace. With remote work becoming the new standard, small businesses are juggling tighter budgets while trying to maintain smooth financial operations. It's a hard game, but here is where Halfpricesoft.com rolls out their newly upgraded multi-user ezCheckPrinting software,...

Continue Reading
VT Markets Appoints Maxwell for Global Expansion

Updated Category News Views 3

Maxwell Joins VT Markets Amid Strategic Shift Forget the usual humdrum of C-suite comings and goings; this one's packed with punch. VT Markets is setting the stage for a serious leap forward by naming Ross Maxwell their new Chief Strategy Officer. This isn't just another desk job—it's a pivotal role meant to integrate cutting-edge technology with the ever-evolving...

Continue Reading
Art and Science Blend in Dr. De La Cruz's Approach

Updated Category News Views 1

Redefining Aesthetic Surgery: An Artistic Approach The world of plastic surgery is often seen through the lens of beauty and symmetry, but for Dr. Emmanuel De La Cruz, it's like staring into a whole different universe. This Houston-based plastic surgeon isn't just removing fat—he's reshaping the human canvas with the eye of a sculptor. Beyond the Standard Cut and Snip...

Continue Reading
Argo Biopharma's BW-20805 Shows Promise in HAE Phase II Trial

Updated Category News Views 0

Argo's Gains in Hereditary Angioedema Therapy Think about it, folks – reducing a hereditary angioedema attack by over 80%? Argo Biopharma, the slick operator in the RNA therapeutics space, is flexing its muscles again. They've hauled in some impressive data for their siRNA therapeutic, BW-20805, at the 2026 Bradykinin Symposium in Berlin. For you deep-pocketed investors...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating Risk Management Challenges in the Banking Sector

Updated Category News Views 547

Understanding the Current Landscape of Risk Management in Banking In recent findings from the Wolters Kluwer Regulatory & Risk Management Indicator survey, there's a notable shift in the concerns of the U.S. banking industry. Approximately half of the respondents reported elevated levels of concern regarding risk management and regulatory compliance efforts. Survey...

Continue Reading
Wendy's Company Delivers Mixed Results in Q3 2025

Updated Category News Views 245

Financial Performance Overview The Wendy's Company (NASDAQ: WEN) has recently shared its performance results for the third quarter, revealing some intriguing dynamics within its financial metrics. Global systemwide sales reached $3.5 billion, reflecting a notable decrease of 2.6%. This decline can largely be attributed to lower same-restaurant sales in the U.S., which...

Continue Reading
Alliance Trust PLC Reports Latest Net Asset Value Figures

Updated Category News Views 125

ALLIANCE TRUST PLC As of the end of business on a recent Wednesday, Alliance Trust PLC has shared its updated Net Asset Value (NAV) per ordinary share, providing valuable insights into its financial standing. Now, what’s the deal with NAV? It’s not just some dry number—it’s essentially a pulse check on how the company is doing financially. In this context, it...

Continue Reading
DeltaPrime Unveils Comprehensive Reimbursement Plan Post-Breach

Updated Category News Views 55

DeltaPrime's Reimbursement Strategy Explained DeltaPrime, a frontrunning DeFi prime brokerage, is taking significant steps to support its users after a recent security breach led to substantial financial loss. The breach, which occurred on September 16, resulted in a loss of approximately $5.98 million on their Deltaprime Blue protocol. In a demonstration of commitment to...

Continue Reading
Seizing Opportunities in the Nuclear Sector Amid Market Fluctuations

Updated Category News Views 126

Understanding the Nuclear Sector's Current Landscape As we analyze the nuclear sector's performance towards the end of the year, it's evident that investors in advanced nuclear technology might feel uneasy. Recent declines in stock prices have raised concerns among shareholders. For instance, Oklo has faced a substantial fall of 36% in the last quarter alone. Similarly,...

Continue Reading